Wanjia Group (0401) Fair Value & Analysis
Healthcare · HK · Market cap HK$142M
Fair value as of: Aug 15, 2026
From 11 valuation models · updated yesterday
Share price +9.2% over the past month.
A solid business, but screening 54% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$0.0700). The favourable scenario is already priced in.
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 15, 2026.
How to read this chart
60‑month range HK$0.0380 – HK$0.7390 · fair‑value band HK$0.0500 – HK$0.0700 · the HK$0.1300 price screens above the HK$0.0600 fair value. Dashed = 300-day average. As of Aug 15, 2026.
Analysis
Wanjia Group (0401) currently trades at HK$0.1300, while our model-based Fair Value estimate is HK$0.0600, implying the stock looks roughly 53.9% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Wanjia Group generated revenue of HK$164M at a net margin of -5.2%. Revenue grew 2.4% year over year. It earns a return on equity of -11.9%. The balance sheet holds a net cash position of HK$12.4M. Fundamentals as of Aug 15, 2026
Our scenario range runs from HK$0.0500 (bear case) to HK$0.0700 (bull case); at HK$0.1300, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high and 164% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -7% fair-value upside, at -54%, 0401 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 11 models by family
Widest divergence: Growth DCF (HK$0.1000) versus Asset-Based (HK$0.0400). Highest evidence: Growth DCF (80).
Notify me when 0401 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 15, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 56
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Wanjia Group Holdings Limited, an investment holding company, engages in the wholesale and distribution pharmaceutical business in the Mainland China and Hong Kong. The company offers hemodialysis treatment and consultancy services.
Full company description
Wanjia Group Holdings Limited, an investment holding company, engages in the wholesale and distribution pharmaceutical business in the Mainland China and Hong Kong. The company offers hemodialysis treatment and consultancy services. It sells its products to hospitals and healthcare institutions; and companies operating pharmaceutical retail chain stores, independent pharmacies, outpatient departments of community hospitals, healthcare service stations, and clinics. Wanjia Group Holdings Limited was founded in 2004 and is headquartered in Kowloon, Hong Kong.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Wanjia Group reported revenue of HK$162M in FY2025 versus HK$114M in FY2021, a compound +9.1%/yr. Reported net income was −HK$6.6M in FY2025.
0401 screens 54% overvalued. Compare with McKesson Corporation →
Peer Group
Medical Distribution · 77 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 15, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $878.73 | $819.31 | -7% |
| Cencora, Inc COR | $314.17 | $211.07 | -33% |
| Cardinal Health, Inc CAH | $234.16 | $141.77 | -39% |
| Henry Schein, Inc HSIC | $90.74 | $71.70 | -21% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.56 | ¥33.96 | +105% |
| Sinopharm Group 1099 | HK$16.75 | HK$58.67 | +250% |
| Galenica AG GALE | CHF 80.85 | CHF 61.79 | -24% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.49 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥5.04 | ¥9.84 | +95% |
| Asker Healthcare Group ASKER | kr 80.00 | kr 28.26 | -65% |
Compare Wanjia Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Wanjia Group (0401) overvalued or undervalued?
What is the fair value of 0401?
What is the quality score of 0401?
What is the revenue of Wanjia Group (0401)?
What is the net profit margin of 0401?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Wanjia Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.